UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (date of earliest event reported): September 30, 2007
MEDICAL
DISCOVERIES, INC
(Exact
Name of Registrant as Specified in Charter)
Utah
(State
of
Incorporation)
000-24569
|
|
87-0407858
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification
No.)
|
|
|
|
1338
S. Foothill Drive, #266, Salt Lake City,
Utah 84108
|
|
84108
|
(Address
of Principal Executive
Offices)
|
|
(Zip
Code)
|
(801)
582-9583
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨ |
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
|
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)).
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)).
|
ITEM
1.01 ENTRY
INTO A MATERIAL AGREEMENT
Amendment
to Asset Sale Agreement
As
previously reported on a Current Report on Form 8-K filed on September 17,
2007,
Medical Discoveries, Inc. (the “Company”),
together with its wholly owned subsidiary MDI Oncology, Inc. (“MDI,”
and
collectively with the Company, the “MDI
Entities”),
entered into a sale and purchase agreement (the “Asset
Sale Agreement”)
with
Eucodis Pharmaceuticals Forschungs - und Entwicklungs GmbH, an Austrian company
(“Eucodis”),
pursuant to which Eucodis agreed to acquire certain assets of the Company
in
consideration for a cash payment and the assumption by Eucodis of certain
current indebtedness of the MDI Entities (such transactions, collectively,
the
“Asset
Sale”).
On
September 30, 2007, the MDI Entities and Eucodis executed an amendment (the
“Amendment”)
to the
Asset Sale Agreement to, among other things, (i) extend the closing of the
Asset
Sale through October 31, 2007, and (ii) correct name of the escrow agent
set
forth therein.
A
copy of
the Amendment is filed as an exhibit to this Current Report on Form 8-K.
The
summary of the Amendment set forth above is qualified by reference to such
exhibit.
ITEM
9.01 EXHIBITS
|
2.1 |
Amendment
to Asset Sale Agreement dated September 30, 2007 among Medical
Discoveries, Inc., MDI Oncology, Inc. and Eucodis Pharmaceuticals
Forschungs - und Entwicklungs
GmbH
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
MEDICAL
DISCOVERIES, INC. |
|
|
|
Date: October
3, 2007
|
By: |
/s/ RICHARD
PALMER |
|
Richard
Palmer |
|
President
|
EXHIBIT
INDEX
2.1 |
Amendment
to Asset Sale Agreement dated September 30, 2007 among Medical
Discoveries, Inc., MDI Oncology, Inc. and Eucodis Pharmaceuticals
Forschungs - und Entwicklungs
GmbH
|